All News

    I’m a Survivor: The Day I Finally Believed It

    June 18th 2025, 5:00pm

    Article

    I finally felt like a survivor the day I heard my 18-month scans were clear, shifting from fear to faith and realizing I was not just surviving — I was thriving.

    The Person Behind Their Diagnosis: Understanding the Patient

    June 18th 2025, 4:26pm

    Article

    Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.

    Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer

    June 18th 2025, 3:00pm

    Article

    Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.

    ctDNA-Guided Therapy May Improve Breast Cancer Outcomes

    June 18th 2025, 1:00pm

    Video

    For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.

    From Navigating the Unknown to Building a Movement: My DCIS Journey

    June 17th 2025, 9:00pm

    Article

    The bad news is you have ductal carcinoma in situ. The good news is that DCIS is the best type of breast cancer to get.

    How Insurance Red Tape Threatens Timely Cancer Care

    June 17th 2025, 7:00pm

    Article

    A study explores how prior authorization requirements; coverage stoppages and other red tape can generate barriers to life saving therapies in cancer care.

    When Cancer and COVID Collide: The Diagnosis That Changed It All

    June 17th 2025, 5:00pm

    Article

    I was diagnosed with follicular lymphoma in 2020, during COVID, which forced me to retire early and taught me I’m more than a statistic.

    Understanding the Importance of the DESTINY-Breast09 Trial in HER2+ Breast Cancer

    June 17th 2025, 4:00pm

    Article

    Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic breast cancer should know.

    Breyanzi Shows Durable Responses in R/R Marginal Zone Lymphoma

    June 17th 2025, 3:00pm

    Article

    Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a durable safety.

    New Treatment Options Emerging Across Lung Cancer Subtypes

    June 17th 2025, 1:00pm

    Video

    Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts.